The efficacy of PD-1 and PD-L1 inhibitors is dependent on patient factors, like (i) gender, (ii) kinds of cancers, (iii) translocation and gene mutation (Kras, EGFR, ALK), and (iv) tumor metastases [124]. This evidence concerns the gene PDCD1 and neoplasm.